The Antengene board today announced the appointment of Mr. Mark J. Alles as an 
independent director of the company, effective January 2, 2020. Mr. Alles is 
the former Chairman and Chief Executive Officer of Celgene Corporation, now a 
subsidiary of Bristol-Myers Squibb Company (BMS). In his 16-year tenure at 
Celgene, Mark led the expansion of the company into a global enterprise serving 
patients with blood cancers, solid tumor cancers and inflammatory diseases. He 
held a series of commercial and leadership roles of escalating responsibility, 
consistently delivering industry-leading financial performance. He led teams 
that completed several multibillion-dollar company and product acquisitions, 
built a diverse suite of globally marketed medicines and a high potential 
pipeline of therapeutics for the treatment of cancer, all of which led to the 
recently completed $74 billion-dollar acquisition of Celgene by BMS. His career 
spans more than three decades, with a distinguished record of driving medical 
innovation for patients worldwide. 

Mark is a recognized industry leader with deep operational, financial, business 
development and commercial experience. He is a former board member of the 
Pharmaceutical Research and Manufacturers of America (PhRMA), the European 
Federation of Pharmaceutical Industries and Associations (EFPIA), the 
Biotechnology Innovation Organization (BIO), Gilda's Club NYC (nonprofit 
helping families of people with cancer), and a former member of the Trustees 
for the Healthcare Institute of New Jersey (HINJ). 

"Mark is an accomplished business leader and an experienced board member in the 
biopharmaceutical industry. He led the growth of Celgene from a US-based 
organization with less than 500 employees, to a global company serving patients 
in more than 50 countries with 8,800 employees," said Dr. Jay Mei, Chairman and 
CEO of Antengene. "We are delighted to have Mark join our board. We are 
confident that he will add great value to our board of directors, and Antengene 
will benefit from his insights, guidance and counsel. Today Antengene is at 
critical stage to accelerate its growth through its strong R&D capabilities and 
evolving commercial infrastructure. Mark brings outstanding governance and 
commercial experience that will help promote our development and commercial 
strategy in China, the Asia Pacific regions and the rest of the world." 

In addition to his role as Chairman and CEO at Celgene, Mr. Alles served in 
various leadership roles during his 32-year industry career, including Vice 
President of the U.S. Oncology business unit at Aventis Pharmaceuticals and 
other senior commercial management roles at Aventis (Rhone-Poulenc Rorer). He 
began his career in the pharmaceutical industry at Bayer and worked at Centocor 
before its acquisition by Johnson & Johnson. 

"Antengene Corporation has rapidly become an important new China-and-U.S. based 
biopharmaceutical company focused on the discovery, development and 
commercialization of novel therapeutics for the treatment of cancer," said Mr. 
Alles. "I am excited to be joining the Antengene Board now and look forward to 
working with the board and management team to deliver on the promise and 
potential of this dynamic organization." 

About Antengene 

Antengene is a China-and-U.S. based biopharmaceutical company focusing on drug 
discovery, clinical development and the commercialization of innovative 
therapeutics to meet unmet medical needs. Antengene aims to provide the most 
advanced and first-in-class anti-cancer drugs and other treatments for patients 
in China/Asia and around the world. Antengene's pipeline includes six clinical 
stage products: ATG-010 (selinexor), in combination with the corticosteroid 
dexamethasone, has been approved by the U.S. Food and Drug Administration, and 
is currently in registration study in China for the treatment of adult patients 
with relapsed or refractory multiple myeloma. The drug is also in late clinical 
development for various other hematologic malignancies and solid tumors. 
ATG-008, a second-generation dual mTORC1/2 inhibitor, is in a multi-regional 
clinical trial for treatment of hepatocellular carcinoma as well as clinical 
studies in multiple other solid tumors. Two other Phase 1 and Phase 2 clinical 
stage drugs, ATG-016 and ATG-019, are being studied in multiple cancer types, 
including colorectal, prostate, NHL, MDS and other solid and hematological 
malignancies. ATG-527 is being explored for multiple anti-viral indications, 
including Epstein-Barr virus (EBV) related diseases. ATG-017 is a potent and 
selective small molecule extracellular signal-egulated kinases 1 and 2 (ERK1/2) 
inhibitor, in clinical development for multiple solid tumors, NHL and AML. The 
drug discovery team of Antengene focuses on the development of first-in-class 
novel molecules with six projects in pre-clinical development, including small 
molecule, monoclonal and bi-specific antibodies. 


SOURCE: Antengene Corporation